Global CTLA-4 Therapies Market Is Expected to Reach USD 1384.4 million by 2030

The global CTLA-4 therapies market is expected to grow from USD 800 million in 2021 to USD 1384.4 million by 2030, at a CAGR of 7.1% during the forecast period 2022-2030. The immunological checkpoint and immune response suppressor CTLA-4, also known as CD152 (cluster of differentiation 152) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), is a protein receptor. The constitutive expression of CTLA-4 in regulatory T cells, as opposed to the overexpression of this protein in conventional T cells after activation, is a trait that is particularly prominent in malignancies. It serves as an "off" switch when affixed to CD80 or CD86 on the surface of antigen-presenting cells. The immunoglobulin superfamily member CTLA-4, generated by activated T cells, transmits an inhibitory signal to T cells. CTLA-4 binds to CD80 and CD86, also known as B7-1 and B7-2, on antigen-presenting cells, similarly to the T-cell co-stimulatory protein CD28.

Market Growth & Trends

Immune checkpoints such as programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 adversely limit T-cell immunological activity (CTLA-4). The suppression of these targets, which enhanced immune system activation, led to the development of novel immunotherapies for melanoma, non-small cell lung cancer, and other malignancies. A CTLA-4 inhibitor called ipilimumab is authorized to treat advanced or incurable melanoma. Ipilimumab and nivolumab in combination have also been approved for use in patients with metastatic or incurable BRAF WT melanoma. CTLA-4 has specific functions that involve inhibiting immune responses, particularly anticancer responses. It is believed that CTLA-4 regulates T-cell proliferation early in the immunological response, particularly in lymph nodes, whereas PD-1 suppresses T cells later in an immune response, primarily in peripheral tissues. Immuno-oncology medicines that inhibit these 2 checkpoints may have various clinical properties because of the molecular variations between them.

Key Findings

In 2022, the autoimmune conditions and immunoglobulins deficits segment accounted for the largest share of the market, with 59% and market revenue of 472 million.

Based on the treatment, the CTLA-4 therapies market is categorized into autoimmune conditions and immunoglobulin deficits, and others. In 2022, autoimmune conditions dominated the market with the largest market share of 59% and market revenue of 472 million. A promising novel treatment is the drug CTLA-4-Ig, also known as abatacept, which mimics the function of the CTLA4 protein and reduces immunological activity. Abatacept is used to treat autoimmune diseases including rheumatoid arthritis, but more studies are required to ascertain whether it may also be used to treat CTLA4 deficiency. In order to determine the effectiveness and safety of intravenous infusions of abatacept for restoring or improving blood cell counts in people with CTLA4 deficiency, researchers from the NIAID started a small clinical investigation in 2019. The study is receiving the drug abatacept, which Bristol-Myers Squibb produces.

In 2022, the clinical & laboratories segment accounted for the largest share of the market, with 40.1% and a market revenue of 320.8 million.

Based on the end-user, the CTLA-4 therapies market is categorized into clinical & laboratories, hospitals, and others. In 2022, the clinics & laboratories segment accounted for the largest share of the market, with 40.1% and market revenue of 320.8 million. The majority of patients experience diarrhea or enteropathy. Hepatosplenomegaly, lymphadenopathy, and autoimmunity are also frequent. Organs affected by autoimmunity include those with thrombocytopenia, hemolytic anemia, thyroiditis, type I diabetes, psoriasis, and arthritis. Respiratory illnesses are also very common. It's important to remember that clinical manifestations and sickness development differ from person to person, with some experiencing severe symptoms while others exhibiting slight disease manifestations. This "variable expressivity" can be observed even within a single family. It may be explained by changes in a person's lifestyle, exposure to pathogens, response to treatment, or additional genetic modifiers.

Regional Segment Analysis of the CTLA-4 Therapies Market

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and Rest of South America)
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)

Among all regions, the North American region emerged as the largest market for the global CTLA-4 therapies market, with a market share of around 39% and 312 million of the market revenue in 2022. The market for CTLA-4 therapeutics has been developing quickly in the Asia Pacific region due to the rising need for t-lymphocyte treatment. Due to the rising incidence of cancer in the region, the use of CTLA-4 medications is at its peak.

Key players operating in the global CTLA-4 therapies market are:

  • AbbVie, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Amgen, Inc.